Rafal Farjo, Ph.D. is chief operating officer of both eyecro and Charlesson, which are involved in research to advance treatments for eye disease such as age-related macular degeneration, diabetic retinopathy and ocular inflammation.
Far from resisting his family’s interest in all things STEM — science, technology, engineering and math — Farjo embraced it.
“I loved it, and I actually started doing research at the University of Michigan not because I wanted to do research but because I was doing my requisite semester of research to get a letter of recommendation for medical school,” he said.
Recently, eyecro was awarded a patent for a platform technology it developed called MiDROPS. It signed a development agreement with a Seattle-based company called NeuMedics.
Read the entire article here.